Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Earnings

Nova Leap Health Corp. Posts Best Financial Performance in Company History with Record Q3 2025 Results

By The Northwire Desk — AI Analysis Nov 06, 2025 · 17:01 NLH · 0.3 Nova Leap Health Corp.
NLH · Price

Executive Summary

  • Nova Leap Health Corp. reported record Q3 2025 consolidated revenues of $8.26 M, a 3% increase versus Q2 2025 and 29% versus Q3 2024.
  • Adjusted EBITDA reached $670,706, up 16.1% from the prior quarter and 76.9% year‑over‑year, marking a new performance benchmark for the company.
  • Net income turned positive at $426,171 after a net loss in Q2 2025, while cash on hand was $1.57 M and the company retained full access to its revolving credit facility and additional acquisition financing of up to $4.69 M.

Key Details

  • Revenue: $8,264,326 (Q3 2025) – +3% vs Q2 2025; +29% vs Q3 2024.
  • Adjusted EBITDA: $670,706 (Q3 2025) – +16.1% vs Q2 2025; +76.9% vs Q3 2024.
  • Gross profit margin: 39.6% of revenue in Q3 2025 (vs 40.2% in Q2 2025 and 38.0% in Q3 2024).
  • Operating cash flow: $418,553 generated in Q3 2025 (+$68,114 vs Q2 2025).
  • Net income: $426,171 (Q3 2025) – reversal from net loss of $484,008 in Q2 2025 and $207,871 loss in Q3 2024.
  • Liquidity: Cash balance $1,571,716 as of Sept 30 2025; unutilized revolving credit facility $1,077,509 (CAD 1.5 M).
  • Leverage: Total demand loans & promissory notes $2,300,800; leverage ratio 1.18× TTM Adjusted EBITDA ($1,950,620).
  • Acquisition financing: Access to up to $4,691,000 under existing credit agreement for future acquisitions.
  • Segment performance: Record revenues, gross margins and Adjusted EBITDA reported for both Canadian and U.S. operating segments (specific segment dollar amounts not disclosed).
  • Insider ownership: Increased during the quarter, reinforcing alignment with shareholders.

Notable Quotes

“Q3 was another record‑breaking quarter for Nova Leap… we have established a new level of performance materially higher than before.” – Chris Dobbin, President & CEO

All figures are presented in U.S. dollars unless otherwise noted.

Read the original news release →

More from Nova Leap Health Corp.

May 07, 2026 · 17:00

Nova Leap’s Q1 shines with record TTM revenue and a bolt-on Nova Scotia acquisition, but the small-cap story still needs to prove scalability beyond the home.

Earnings May 01, 2026 · 07:55

Nova Leap Executes Growth Strategy with Parkwood Acquisition, Boosting EBITDA by 28% While Tightening Liquidity

M&A / Property Mar 05, 2026 · 17:15

President & CEO Letter to Shareholders

Other Mar 05, 2026 · 17:13

Nova Leap Health Corp. Posts Fourth Quarter and Record Full-Year 2025 Revenues and Adjusted EBITDA

Earnings Feb 02, 2026 · 14:22

Nova Leap sets up palliative care division in N.S.

Production / Operations Feb 02, 2026 · 07:00

Nova Leap Health Corp. Launches Palliative Care Division In Nova Scotia Through Earth Angels Home Care

Production / Operations